Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important curative
therapy for patients with leukemia. However, relapse remains the leading cause of death …

Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid
leukemia (AML) represents the only curative option. Progress has been made in the last two …

This study was performed to assess the utility of tumor-derived fragmentary DNA, or
circulating tumor DNA (ctDNA), for identifying high-risk patients for relapse of acute myeloid …

For allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, preemptive
interferon-α (IFN-α) therapy is considered as a useful method to eliminate the minimal …

Relapse remains the leading cause of treatment failure in children with acute lymphoblastic
leukaemia (ALL) undergoing allogeneic haematopoietic stem cell transplantation (HSCT) …

Donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation
(allo-HSCT) has been widely used in preventing post-transplant relapse. We conducted this …

Gene mutation has been considered a research hotspot, and the rapid development of
biomedicine has enabled significant advances in the evaluation of gene mutations. The …

Recipient–donor chimerism is routinely analyzed after allogeneic hematopoietic stem cell
transplantation (HSCT) to monitor engraftment and graft rejection. For malignancies …

As an important treatment for acute myeloid leukemia, allogeneic hematopoietic stem cell
transplantation (allo-HSCT) plays an important role in reducing relapse and improving long …

* Correspondence: mxd453@ 163. com (XM); gen. yang@ pku. edu. cn (GY) Received:
December 25, 2022; Accepted: March 2, 2023; Published Online: March 5, 2023; https://doi …